简繁EN
Antengene

Company Introduction

3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.

MORE

April 2021

04
04
04
04
04
04
04
March 2020
October 2020
November 2020
December 2020
January 2021
March 2021
April 2021

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

Candidate
Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Partner

  • Envafolimab
  • PD-L1
  • Worldwide

  • MSI-H/dMMR advanced cancer (mono, 2L+, ORR, tissue agnostic indication)

  • BTC (combo with chemo vs. chemo, randomized, OS, 1L)

  • Sarcoma (mono, +ipilimumab, ORR, 2L+)

  • NSCLC (vs standard treatment)

  • NSCLC (combo, 2L+)

  • Urothelial cancer (mono vs. BSC, 1L maintenance, MRCT)

  • G/GEJ advanced cancer (combo with chemo, 1L)

  • TMB-H advanced cancer (2L+ mono)

  • Endometrial cancer (mono, combo with lenvatinib, 2L+)

  • HCC (combo with VEGF inhibitor, 2L+)

  • Renal cell carcinoma (combo with VEGF inhibitor, 1L/ 2L+)

  • Alphamab Group
    Simcere Group
    TRACON

MORE

  • 3D189
  • WT1
  • Great China

  • Multiple indications

  • AML/MPM/OC/MM

    (Conducted by SELLAS, a licensor of 3D189)

  • SELLAS Group

MORE

  • 3D229
  • GAS6/AXL
  • Great China

  • NSCLC/OC/RCC/UC

  • OC/RCC/UC

    ( MRCT)

  • OC/RCC/UC

    (Conducted by Aravive, a licensor of 3D229)

  • Aravive

MORE

  • 3D1001
  • COX-2
  • China

  • Post-surgical dental pain/cancer pain

  • Haihe Biopharma Group

MORE

  • 3D1002
  • EP-4
  • China

  • Cancer pain / osteoarthritis

  • Haihe Biopharma Group

MORE

  • 3D185
  • FGFR1/2/3
  • Worldwide

  • Solid tumors / BTC / UC

  • Haihe Biopharma Group & SIMM

MORE

  • 3D011
  • TKI prodrug
  • Worldwide

  • HCC / RCC / PC

    IND approved, acceptance notice: CXHL2000597

MORE

  • 3D197
  • CD47
  • Great China

  • Multiple indications

  • Multiple indications

    (Conducted by ImmuneOncia, a licensor of 3D197)

  • ImmuneOncia

MORE

  • 3D057
  • CD3+PD-L1
  • Greater China + Worldwide Priority Transfer right

  • Multiple indications

  • Y-Biologics

MORE

  • 3D059
  • WT1
  • Greater China

  • Multiple indications

  • SELLAS Group

MORE

  • 3D060
  • Sema4D
  • Worldwide

  • Multiple indications

MORE

  • 3D062
  • KRAS
  • Worldwide

  • Multiple indications

MORE

Pipeline

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D059
  11. 3D060
  12. 3D062

CEO MESSAGE

"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.

With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."


-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

MORE

Company News

MORE

Copyright © 3D Medicines Inc. All Rights Reserved